Total Revenue

Down approximately 35.6% (from $4.531M in Q4 2023 to $2.917M in Q4 2024)

Total Revenue declined significantly due to lower sales or market demand compared to the previous period, suggesting that pricing or volume challenges may have adversely affected top-line performance. This decrease has set the stage for increased losses despite adjustments or cost reduction efforts in earlier periods. " " "

Operating Loss

Increased by roughly 36% (from $26.436M in Q4 2023 to $36.107M in Q4 2024)

Operating Loss widened as the decline in revenue was compounded by higher operating costs, including increased R&D and general and administrative expenses; the previous period's lower cost base made the performance gap more pronounced in Q4 2024. " " "

Net Loss

Increased by about 40% (from $27.450M in Q4 2023 to $38.369M in Q4 2024)

Net Loss grew further due to the combined impact of higher operating losses and elevated non-operating expenses, indicating challenges in controlling costs amid a revenue downturn relative to the previous period’s financial structure. " " "

Research and Development Expenses

Increased 28% (from $12.829M in Q4 2023 to $16.475M in Q4 2024)

R&D expenses increased notably, reflecting intensified investment in new product development and clinical programs; while these increased costs signal commitment to future growth, they have also contributed to the short-term deterioration in profitability compared to the prior period. " " "

Interest Expense

Increased approximately 122% (from $1.962M in Q4 2023 to $4.366M in Q4 2024)

Interest Expense more than doubled, indicating that the company took on considerably higher borrowings or encountered less favorable financing terms, sharply increasing its financing costs over the previous period. " " "

General and Administrative Expenses

Increased about 23.7% (from $17.145M in Q4 2023 to $21.195M in Q4 2024)

G&A expenses grew significantly, likely driven by higher personnel costs, legal fees, and commercial expense outlays related to market expansion or litigation, marking a continuation of cost increases seen in prior periods but at a magnified level in Q4 2024. " " "